Off-pump surgery for the poor ventricle?

Maximilian Y Emmert1, Sacha P Salzberg, Oliver M Theusinger

  • 1Department of Cardiovascular Surgery, University Hospital Zurich, Raemi Street 100, 8091, Zurich, Switzerland. maximilian.emmert@web.de

Heart and Vessels
|May 18, 2011
PubMed

Insights

Off-pump coronary artery bypass grafting (OPCAB) is safe for patients with severely reduced ejection fraction (EF), showing similar mortality and major adverse cardiac and cerebrovascular events (MACCE) compared to on-pump CABG (ONCABG). OPCAB may reduce non-cardiac complications without compromising complete revascularization.

Area of Science:

  • Cardiovascular Surgery
  • Cardiac Anesthesia

Background:

  • Severely decreased ejection fraction (EF) is a significant risk factor for adverse outcomes following cardiac surgery.
  • Comparing surgical techniques in patients with compromised EF is crucial for optimizing patient care.

Purpose of the Study:

  • To compare the outcomes of off-pump coronary artery bypass grafting (OPCAB) versus on-pump CABG (ONCABG) in patients with severely reduced EF (≤35%).
  • To assess the safety, efficacy, and complication rates of OPCAB versus ONCABG in this high-risk population.

Main Methods:

  • A cohort of 478 patients with EF ≤35% undergoing myocardial revascularization between 2004-2009 were analyzed.
  • Patients received either OPCAB (n=256) or ONCABG (n=222).
  • Propensity score (PS) matching and adjusted logistic regression were used to compare mortality, MACCE, and non-cardiac complications.

Main Results:

  • No significant differences were observed in mortality (2.3% vs. 4.1%) or MACCE (13.7% vs. 17.6%) between OPCAB and ONCABG groups.
  • OPCAB showed a trend towards fewer non-cardiac complications (12.1% vs. 22.1%), including renal dysfunction and bleeding.
  • The rate of complete revascularization was similar between the two groups (92.2% vs. 92.8%).

Conclusions:

  • Off-pump coronary artery bypass grafting (OPCAB) is a safe and feasible option for patients with severely decreased ejection fraction.
  • OPCAB may offer a potential benefit in reducing non-cardiac complications without compromising the completeness of revascularization.
  • These findings support OPCAB as a viable alternative for myocardial revascularization in high-risk patients with compromised cardiac function.